OBSV News and Press, ObsEva SA From 08/04/21

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction - - A Mechanism of Action T rial ...

GENEVA, Switzerland August 3 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate u...

Gainers: Intrusion (INTZ) +65%.MOGU (MOGU) +40%.Oragenics (OGEN) +32%.BiondVax Pharmaceuticals (BVXV) +29%.Sintx Technologies (SINT) +23%.Dyadic International (DYAI) +21%.EyeGate Pharmaceuticals (EYEG) +19%.U.S. Physical Therapy (USPH) +18%.ObsEva SA (OBSV) +16%.Orbsat (OSAT) +15%.Losers: IRS...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Greetings, trader! Join me as we dive into the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.com But before that, check out our overview of important stock stories from Monday. The extra...

TolikoffPhotography/iStock via Getty Images Organon (OGN) and ObsEva (OBSV) have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022), being evaluated as a potential treatment for preterm labor by reducing in...

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Gene...

Current & Former Biotech Penny Stocks To Watch This Week Is the stock market going to crash? What are the best penny stocks to buy right now? Will July bring new highs in the stock market in 2021? These are just a few of the many questions being asked as we embark on the second ...

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia – GENEVA, Switzerland and BOSTON – July 2 , 2021 – ObsEva...

ObsEva (OBSV) announces clinical data from a pilot study on Yselty (linzagolix) for the treatment of severe adenomyosis.Additionally, 52-week data from two Phase 3 studies of Yselty for the treatment of uterine fibroids, as well as results from an analysis of uterine contractility in women wh...

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer - GENEVA, Switzerland and BOSTON – June 30 , 202...